Drug Safety Evaluation (eBook)
918 Seiten
John Wiley & Sons (Verlag)
978-1-119-09740-2 (ISBN)
* Helps readers solve scientific, technical, and regulatory issues in preclinical safety assessment and early clinical drug development
* Explains scientific and philosophical bases for evaluation of specific concerns - including local tissue tolerance, target organ toxicity and carcinogenicity, developmental toxicity, immunogenicity, and immunotoxicity
* Covers the development of new small and large molecules, generics, 505(b)(2) route NDAs, and biosimilars
* Revises material to reflect new drug products (small synthetic, large proteins and cells, and tissues), harmonized global and national regulations, and new technologies for safety evaluation
* Adds almost 20% new and thoroughly updates existing content from the last edition
Shayne Cox Gad, BS, PhD, DABT, has more than 39 years of experience in regulatory toxicology, drug and device development, statistics, and risk assessment. He is Principal of Gad Consulting Services, a firm with eight employees and more than 500 clients worldwide in the pharmaceutical and medical device industries. He is Past President of the American College of Toxicology (ACT), the Roundtable of Toxicology Consultants, and three of the Society of Toxicology's specialty sections. Dr. Gad received the 2008 ACT Lifetime Contribution Award and has authored or edited 47 books (10 with Wley) and more than 350 chapters, articles, and abstracts. Has preparated 110 INDs and 8 NDAs and teaches 3-5 professional education courses a year.
Preface: ix
About the Author xi
Chapter 1: The Drug Development Process and the Global Pharmaceutical Marketplace
Chapter 2: Regulation of Human Pharmaceutical Safety: Routes to Human Use and Market
Chapter 3: Data Mining: Sources of Information for Consideration in Study and Program Design and in Safety Evaluation
Chapter 4: Screens in Safety and Hazard Assessment
Chapter 5: Formulations, Routes, and Dosage Regimens
Chapter 6: Nonclinical Manifestations, Mechanisms and Endpoints of Drug Toxicity
Chapter 7: Pilot Toxicity Testing in Drug Safety Evaluation: MTD and DRF
Chapter 8: Repeat Dose Toxicity Studies
Chapter 9: Genotoxicity
Chapter 10: QSAR Tools for Drug Safety
Chapter 11: Immunotoxicology in Drug Development
Chapter 12: Nonrodent Animal Studies
Chapter 13: Developmental and Reproductive Toxicity Testing
Chapter 14: Carcinogenicity Studies
Chapter 15: Histopathology in Nonclinical Pharmaceutical Safety Assessment
Chapter 16: Irritation and Local Tissue Tolerance in Pharmaceutical Safety Assessment
Chapter 17: Pharmacokinetics and Toxicokinetics in Drug Safety Evaluation
Chapter 18: Safety Pharmacology
Chapter 19: Special Concerns for the Preclinical Evaluation of Biotechnology Products
Chapter 20: Safety Assessment of Inhalant Drugs and Dermal Route Drugs
Chapter 21: Special Case Products: Imaging Agents
Chapter 22: Special Case Products: Drugs for the Treatment of Cancer
Chapter 23: Pediatric Product Safety Assessment (2006 Guidance, Including Juvenile Toxicology)
Chapter 24: Imaging, Imaging Agents and Radiopharmaceuticals in Nonclinical Toxicology
Chapter 25: Occupational Toxicology in the Pharmaceutical Industry
Chapter 26: Strategy and Phasing for Non Clinical Drug Safety Evaluation in the Discovery and Development of Pharmaceuticals
Chapter 27: The Application of In Vitro Techniques in Drug Safety Assessment
Chapter 28: Evaluation of Human Tolerance and Safety in Clinical Trials: Phase I and Beyond
Chapter 29: Postmarketing Safety Evaluation: Monitoring, Assessing, and Reporting of Adverse Drug Responses (ADRs)
Chapter 30: Statistics in Pharmaceutical Safety Assessment
Chapter 31: Combination Products: Drugs and Devices
Chapter 32: Qualification of Impurities, Degradants, Residual Solvents, Metals and Leachables in Pharmaceuticals
Chapter 33: Tissue, Cell and Gene Therapy
Appendix A: Selected Regulatory and Toxicological Acronyms
Appendix B: Definition of Terms and Lexicon of Clinical Observations in Nonclinical (Animal) Studies
Appendix C: Notable Regulatory Internet Address
Appendix D: Glossary of Terms Used in the Clinical Evaluation of Therapeutic Agents
Appendix E: Common Vehicles for the Non Clinical Evaluation of Therapeutic Agents
Appendix F: Global Directory of Contract Toxicology Labs
"The stated goal of the third edition of Drug Safety Evaluation is to present an all-inclusive practical guide of how the safety of human drugs and biologics are evaluated. One just needs to peruse the table of contents to see that this book provides a comprehensive overview of human drug development as it applies to safety. The content encompasses the regulatory process for small molecules and biologics, and includes detailed descriptions of the toxicological tests that can be conducted and how the results are evaluated"... "Although the content is clearly meant for human pharma, this book will be useful to those involved in safety evaluations for veterinary drug development. The in-depth explanations of how data are evaluated from toxicity studies conducted for human drug development can be applied to animal drug development. The chapter on statistics in pharmaceutical safety assessment is particularly useful, with assumptions and limitations provided for each of the common statistical tests"...... "This comprehensive book on drug safety evaluation is a welcomed addition to my reference library" (Reviewed by Lesley C. Rausch-Derra, DVM, MS, Scout Bio Inc, Kansas City, Mo 15th June 2017)
| Erscheint lt. Verlag | 18.11.2016 |
|---|---|
| Reihe/Serie | Pharmaceutical Development | Pharmaceutical Development |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Gesundheitsfachberufe |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Naturwissenschaften ► Biologie ► Biochemie | |
| Naturwissenschaften ► Chemie | |
| Technik ► Medizintechnik | |
| Schlagworte | Arzneimittelsicherheit • Chemie • Chemistry • Medical Science • Medizin • Pharmacology & Pharmaceutical Medicine • Pharmakologie • Pharmakologie u. Pharmazeutische Medizin • Toxicology • Toxikologie • Veterinärmedizin • Veterinärmedizin / Pharmakologie, Toxikologie, Therapeutik • Veterinärmedizin • Veterinärmedizin / Pharmakologie, Toxikologie, Therapeutik • Veterinary Medicine • Veterinary Pharmacology, Toxicology & Therapeutics |
| ISBN-10 | 1-119-09740-1 / 1119097401 |
| ISBN-13 | 978-1-119-09740-2 / 9781119097402 |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
PDF (Adobe DRM)Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
